Therapieoption mit Botulinumtoxin für Patienten mit Parkinson

U. M. Fietzek; M. Messner; A. Ceballos-Baumann

doi:10.1055/s-0038-1633381

Nervenheilkunde, Inhaltsverzeichnis

Nervenheilkunde 2013; 32(12): 949-953
DOI: 10.1055/s-0038-1633381

Botulinumtoxin

Schattauer GmbH

Therapieoption mit Botulinumtoxin für Patienten mit Parkinson

Therapy options with botulinum toxin for patients with Parkinson’s disease

U. M. Fietzek

¹Abteilung Neurologie und klinische Neurophysiologie, Zentrum für Parkinson-Syndrome und Bewegungsstörungen, Schön Klinik, München Schwabing

,

M. Messner

¹Abteilung Neurologie und klinische Neurophysiologie, Zentrum für Parkinson-Syndrome und Bewegungsstörungen, Schön Klinik, München Schwabing

,

A. Ceballos-Baumann

¹Abteilung Neurologie und klinische Neurophysiologie, Zentrum für Parkinson-Syndrome und Bewegungsstörungen, Schön Klinik, München Schwabing

› Institutsangaben

Abstract

Zusammenfassung

Im Schatten der anderen Therapieoptionen bei Parkinson-Syndromen hat sich die Injektion von Botulinumtoxin für eine Reihe von Indikationen zum unverzichtbaren Helfer gemacht. Hierzu gehören vor allem die Sialorrhoe des Parkinson-Patienten und therapierefraktäre Dystonien des Gesichtes (Blepharospasmus) sowie der Extremitäten (Off-Dystonien). Der Beitrag nennt die Indikation, die verfügbare Evidenz und eine pragmatische Herangehensweise. Die Empfehlung der Autoren zu jeder Indikation sowie deren Zulassungsstatus wird benannt.

Summary

In the backwater of the other therapy modalities for Parkinson syndromes, botulinum toxin type A injection has evolved as a notto-miss option for a number of indications. These are sialorrhea of patients with Parkinson’s disease and therapy-refractory dystonia of the face (blepharospasm) or the extremities (off dystonia). The paper reports the indications, the available evidence, and a pragmatic approach. The authors’ recommendations are given as well as the label status of the various indications.

Schlüsselwörter

Parkinson - Botulinumtoxin - Dystonie - Sialorrhoe

Keywords

Parkinson’s disease - botulinum toxin - dystonia - sialorrhea

Volltext

Referenzen

Literatur
1 Chou KL, Evatt M, Hinson V, Kompoliti K. Sialorrhea in Parkinson’s disease: a review. Mov Disord Off J Mov Disord Soc 2007; 22: 2306-13.
2 Cersósimo MG, Tumilasci OR, Raina GB, Benarroch EE, Cardoso EM, Micheli F. et al. Hyposialorrhea as an early manifestation of Parkinson disease. Auton Neurosci Basic Clin 2009; 150: 150-1.
3 Storch A, Schneider CB, Wolz M, Stürwald Y, Nebe A, Odin P. et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013; 80: 800-9.
4 Bushmann M, Dobmeyer SM, Leeker L, Perlmutter JS. Swallowing abnormalities and their response to treatment in Parkinson’s disease. Neurology 1989; 39: 1309-14.
5 Bloem BR, Kalf JG, van de Kerkhof PCM, Zwarts MJ. Debilitating consequences of drooling. J Neurol 2009; 256: 1382-3.
6 Friedman A, Potulska A. Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. Park Relat Disord 2001; 07: 329-32.
7 Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000; 54: 244-7.
8 Tumilasci OR, Cersósimo MG, Belforte JE, Micheli FE, Benarroch EE, Pazo JH. Quantitative study of salivary secretion in Parkinson’s disease. Mov Disord Off J Mov Disord Soc 2006; 21: 660-7.
9 Guidubaldi A, Fasano A, Ialongo T, Piano C, Pompili M, Mascianà R. et al. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson’s disease. Mov Disord Off J Mov Disord Soc 2011; 26: 313-9.
10 Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord Off J Mov Disord Soc 2006; 21: 704-7.
11 Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G. et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 2003; 18: 685-8.
12 Svetel M, Vasiæ M, Dragaseviæ N, Pekmezoviæ T, Petroviæ I, Kostiæ V. Botulinum toxin in the treatment of sialorrhea. Vojn Pregl Mil-Med Pharm Rev 2009; 66: 9-12.
13 Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R. et al. The movement disorder society evidence-based medicine review Uupdate: Treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord Off J Mov Disord Soc 2011; 26 Suppl 3: S42-80.
14 Yuan M, Shelton J. Acute sialadenitis secondary to submandibular calculi after botulinum neurotoxin injection for sialorrhea in a child with cerebral palsy. Am J Phys Med Rehabil Assoc Acad Physiatr 2011; 90: 1064-7.
15 Chan KH, Liang C, Wilson P, Higgins D, Allen GC. Long-term safety and efficacy data on botulinum toxin type A: an injection for sialorrhea. JAMA Otolaryngol Head Neck Surg 2013; 139: 134-8.
16 Rivest J, Quinn N, Marsden CD. Dystonia in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Neurology 1990; 40: 1571-8.
17 Tommasi G, Krack P, Fraix V, Pollak P. Effects of varying subthalamic nucleus stimulation on apraxia of lid opening in Parkinson’s disease. J Neurol 2012; 259: 1944-50.
18 Aramideh M, Ongerboer de Visser BW, Devriese PP, Bour LJ, Speelman JD. Electromyographic features of levator palpebrae superioris and orbicularis oculi muscles in blepharospasm. Brain J Neurol 1994; 117 (Pt 1): 27-38.
19 Ceballos-Baumann AO, Conrad B. On the differential diagnosis and classification of blepharospasm. J Neurol 1992; 239 (Suppl. 03) 69.
20 Alderson K, Holds JB, Anderson RL. Botulinuminduced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology 1991; 41: 1800-5.
21 Arthurs B, Flanders M, Codere F, Gauthier S, Dresner S, Stone L. Treatment of blepharospasm with medication, surgery and type A botulinum toxin. Can J Ophthalmol 1987; 22: 24-8.
22 Berlin AJ, Cassen JH, DeNelsky G, Hanson MR, Sweeney PJ. Benign essential blepharospasm treated with botulinum toxin. Cleve Clin J Med 1987; 54: 421-6.
23 Elston JS, Russell RW. Effect of treatment with botulinum toxin on neurogenic blepharospasm. Br Med J 1985; 290: 1857-9.
24 Aramideh M, Ongerboer de Visser BW, Brans JW, Koelman JH, Speelman JD. Pretarsal application of botulinum toxin for treatment of blepharospasm. J Neurol Neurosurg Psychiatry 1995; 59: 309-11.
25 Sheffield JK, Jankovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson’s disease. Expert Rev Neurother 2007; 07: 637-47.
26 Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G. “Off “ painful dystonia in Parkinson’s disease treated with botulinum toxin. Mov Disord Off J Mov Disord Soc 1995; 10: 333-6.
27 Limousin P, Memin B, Pollak P. Treatment of dystonia occurring in parkinsonian syndromes by botulinum toxin. Eur Neurol 1997; 37: 66-7.
28 Müller J, Wenning GK, Wissel J, Seppi K, Poewe W. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol 2002; 249: 300-4.
29 Fietzek UM, Schroeder AS, Wissel J, Heinen F, Berweck S. Split-screen video demonstration of sonography-guided muscle identification and injection of botulinum toxin. Mov Disord Off J Mov Disord Soc 2010; 25: 2225-8.
30 Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995; 45: 712-7.
31 Polo KB, Jabbari B. Botulinum toxin-A improves the rigidity of progressive supranuclear palsy. Ann Neurol 1994; 35: 237-9.
32 Chaudhuri KR, Martinez-Martin P, Schapira AHV, Stocchi F, Sethi K, Odin P. et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord Off J Mov Disord Soc 2006; 21: 916-23.
33 Martinez-Martin P, Schapira AHV, Stocchi F, Sethi K, Odin P, MacPhee G. et al. Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord Off J Mov Disord Soc 2007; 22: 1623-9.
34 Sakakibara R, Shinotoh H, Uchiyama T, Sakuma M, Kashiwado M, Yoshiyama M. et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci Basic Clin 2001; 92: 76-85.
35 Uchiyama T, Sakakibara R, Hattori T, Yamanishi T. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson’s disease patients with the wearing-off phenomenon. Mov Disord Off J Mov Disord Soc 2003; 18: 573-8.
36 Kay G, Crook T, Rekeda L, Lima R, Ebinger U, Arguinzoniz M. et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006; 50: 317-26.
37 Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001; 41: 636-44.
38 Kalsi V, Gonzales G, Popat R, Apostolidis A, Elneil S, Dasgupta P. et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007; 62: 452-7.
39 Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000; 164: 692-7.
40 Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C. et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 2007; 41: 335-40.
41 Reitz A, von Tobel J, Stöhrer M, Kramer G, Del Popolo G, Pannek J. et al. European experience of 184 cases treated with botulinum a toxin injections into the detrusor muscle for neurogenic incontinence. Neurourol Urodyn 2002; 21: 427-8.
42 Schurch B, Hodler J, Rodic B. Botulinum A toxin as a treatment of detrusor-shincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. J Neurol Neurosurg Psychiatr 1997; 63: 474-6.
43 Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson’s disease and multiple system atrophy. J Urol 2009; 182: 1453-7.
44 Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, Fabbrini G. et al. Botulinum toxin type A in patients with Parkinson’s disease and refractory overactive bladder. J Urol 2011; 186: 960-4.
45 Kulaksizoglu H, Parman Y. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons’s disease. Parkinsonism Relat Disord 2010; 16: 531-4.
46 Vaughan CP, Juncos JL, Burgio KL, Goode PS, Wolf RA, Johnson TM. Behavioral therapy to treat urinary incontinence in Parkinson disease. Neurology 2011; 76: 1631-4.
47 Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord Off J Mov Disord Soc 2006; 21: 1856-63.
48 Azher SN, Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology 2005; 65: 355-9.
49 Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon Off J Int Soc Toxinology 2009; 54: 614-23.
50 Von Coelln R, Raible A, Gasser T, Asmus F. Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord Off J Mov Disord Soc 2008; 23: 889-92.
51 Colosimo C, Salvatori FM. Injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord Off J Mov Disord Soc 2009; 24: 316-7.
52 Fietzek UM, Schroeteler FE, Ceballos-Baumann AO. Goal attainment after treatment of parkinsonian camptocormia with botulinum toxin. Mov Disord Off J Mov Disord Soc 2009; 24: 2027-8.
53 Gerton BK, Theeler B, Samii A. Backpack treatment for camptocormia. Mov Disord Off J Mov Disord Soc 2010; 25: 247-8.
54 Bonanni L, Thomas A, Varanese S, Scorrano V, Onofrj M. Botulinum toxin treatment of lateral axial dystonia in Parkinsonism. Mov Disord Off J Mov Disord Soc 2007; 22: 2097-103.
55 Giladi N, Nieuwboer A. Understanding and treating freezing of gait in parkinsonism, proposed working definition, and setting the stage. Mov Disord 2008; 23 (Suppl. 02) S423-5.
56 Morris ME, Iansek R, Matyas TA, Summers JJ. Stride length regulation in Parkinson’s disease. Normalization strategies and underlying mechanisms. Brain 1996; 119 (Pt 2): 551-68.
57 Giladi N, Honigman S. Botulinum toxin injections to one leg alleviate freezing of gait in a patient with Parkinson’s disease. Mov Disord 1997; 12: 1085-6.
58 Gurevich T, Peretz C, Moore O, Weizmann N, Giladi N. The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson’s disease: a double blind placebo-controlled pilot study. Mov Disord 2007; 22: 880-3.
59 Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL. et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001; 56: 1523-8.
60 Schneider SA, Edwards MJ, Cordivari C, Macleod WN, Bhatia KP. Botulinum toxin A may be efficacious as treatment for jaw tremor in Parkinson’s disease. Mov Disord Off J Mov Disord Soc 2006; 21: 1722-4.